Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Genentech
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00472693
First received: May 11, 2007
Last updated: January 31, 2013
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)